Blisibimod - Anthera Pharmaceuticals

Drug Profile

Blisibimod - Anthera Pharmaceuticals

Alternative Names: A-623; AMG-623; Blisibimod

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Anthera Pharmaceuticals
  • Class Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 28 Aug 2017 Updated efficacy and adverse events data from the phase II BRIGHT-SC trial in IgA nephropathy released by Anthera Pharmaceuticals
  • 28 Aug 2017 Anthera Pharmaceuticals completes the phase II BRIGHT-SC trial in IgA nephropathy (Combination therapy, Treatment-experienced) in Hong Kong, South Korea, Malaysia, Philippines, Singapore, Taiwan, Czech Republic, Germany, United Kingdom, Italy, Hungary, Sweden, Spain and Thailand (EudraCT2014-001365-26) (NCT02062684)
  • 28 Aug 2017 Anthera Pharmaceuticals plans a phase III trial for IgA Nephropathy in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top